Craniopharyngioma in Children

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Subtypes and drivers:
    • ACP: childhood, cystic, calcified, CTNNB1.
    • PCP: adult, solid, BRAF V600E, which responds to BRAF–MEK inhibition (94%) .
  • Hypothalamic involvement (Puget grade) predicts morbidity. Plan the resection by grade .
  • Spare the posterior hypothalamus:
    • Gains: better quality of life and less obesity.
    • Cost: lower PFS, but survival stays around 100% .
  • Subtotal resection plus radiotherapy ≈ GTR for control: 5-year PFS 73% vs. 77%; subtotal resection alone, 43% .
  • Limited surgery plus proton therapy (RT2CR):
    • Control: 3-year PFS 97%.
    • Benefit over photons: better cognition, not better survival .
  • Early post-radiation cyst growth is usually benign. Don't call it progression .

Landmark papers

  • KRANIOPHARYNGEOM 2007 (Bogusz et al., Endocr Connect 2019): 169 children. Overall survival was 100%, and posterior hypothalamus-sparing surgery gave better quality of life and less obesity at the price of lower progression-free survival .
  • RT2CR (Merchant et al., Lancet Oncol 2023): a single-arm phase 2 study (94 children aged 0–21) of limited surgery plus 54 Gy proton therapy. 3-year PFS was 96.8% and overall survival 100% .
  • BRAF–MEK inhibition (Brastianos et al., N Engl J Med 2023): a phase 2 study of vemurafenib plus cobimetinib before radiation in 16 patients with papillary craniopharyngioma. 15 of 16 (94%) had a durable partial response or better .

Craniopharyngioma is a histologically benign epithelial tumor of the sellar–suprasellar region. Long-term survival is high, but it is one of the most morbid tumors in pediatric neurosurgery, because its neighbors are:

The modern goal is tumor control with hypothalamic preservation, not gross total resection at any cost .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:craniopharyngioma:55bf34abe7c1b48e© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Midsagittal adamantinomatous craniopharyngioma with a multilobulated cyst and calcified solid part compressing the chiasm, pushing up the third ventricle floor and abutting the hypothalamus; Puget hypothalamic grades 0 to 2; and treatment by endoscopic endonasal surgery, cyst catheter with Ommaya reservoir and proton radiotherapy(A) ADAMANTINOMATOUS CRANIOPHARYNGIOMA (MIDSAGITTAL, ANTERIOR LEFT)optic chiasmcompressedsphenoid sinusdilated lateral ventricle(obstruction at the foramen of Monro)third ventricle floor pushed upmultilobulated cyst("machinery-oil" fluid)hypothalamus (abutted)mammillary bodysolid part with calcificationpituitary stalkpituitary gland in the sellabasilar artery(B) PUGET HYPOTHALAMIC INVOLVEMENTgrade 0no involvementgrade 1abuts or displacesgrade 2invaded, not identifiable(C) TREATMENT OPTIONSendoscopic endonasal corridorthrough the sphenoid sinuscyst catheter to an Ommayareservoir (drainage, intracystictherapy)proton beam radiotherapyfor residual tumorschematic; not to scale
Craniopharyngioma in children. (a) A cystic and calcified adamantinomatous craniopharyngioma compressing the optic chiasm, elevating the floor of the third ventricle and causing hydrocephalus. (b) Hypothalamic involvement grades 0–2. (c) Treatment options: endoscopic endonasal resection, cyst catheter with an Ommaya reservoir, and proton therapy for residual tumor. Original schematic.

Biology and presentation

Hypothalamic involvement drives outcome

Surgery

Radiotherapy

Targeted therapy

Related topics

References

  1. Müller HL, Merchant TE, Warmuth-Metz M, et al. Craniopharyngioma. Nat Rev Dis Primers 2019;5(1):75. doi:10.1038/s41572-019-0125-9. PMID 31699993. verified
  2. Bogusz A, Boekhoff S, Warmuth-Metz M, et al. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr Connect 2019;8(5):481–492. doi:10.1530/EC-19-0074. PMID 30925462. verified
  3. Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014;46(2):161–165. doi:10.1038/ng.2868. PMID 24413733. verified
  4. Puget S, Garnett M, Wray A, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 2007;106(1 Suppl):3–12. doi:10.3171/ped.2007.106.1.3. PMID 17233305. verified
  5. Clark AJ, Cage TA, Aranda D, et al. A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma. Childs Nerv Syst 2013;29(2):231–238. doi:10.1007/s00381-012-1926-2. PMID 23089933. verified
  6. Elliott RE, Jane JA Jr, Wisoff JH. Surgical management of craniopharyngiomas in children: meta-analysis and comparison of transcranial and transsphenoidal approaches. Neurosurgery 2011;69(3):630–643. doi:10.1227/NEU.0b013e31821a872d. PMID 21499159. verified
  7. Merchant TE, Hoehn ME, Khan RB, et al. Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study. Lancet Oncol 2023;24(5):523–534. doi:10.1016/S1470-2045(23)00146-800146-8). PMID 37084748. verified
  8. Frassanito P, Massimi L, Bianchi F, et al. Targeted treatment of pediatric craniopharyngioma: lesson learnt after 20-year experience with intracystic interferon alpha. Adv Tech Stand Neurosurg 2025;55:93–110. doi:10.1007/978-3-031-90762-3_5. PMID 40608102. verified
  9. Friedrich C, Boekhoff S, Bischoff M, et al. Outcome after proton beam therapy versus photon-based radiation therapy in childhood-onset craniopharyngioma patients: results of KRANIOPHARYNGEOM 2007. Front Oncol 2023;13:1180993. doi:10.3389/fonc.2023.1180993. PMID 37965466. verified
  10. Bischoff M, Khalil DA, Frisch S, et al. Outcome after modern proton beam therapy in childhood craniopharyngioma: results of the prospective registry study KiProReg. Int J Radiat Oncol Biol Phys 2024;120(1):137–148. doi:10.1016/j.ijrobp.2024.03.015. PMID 38492813. verified
  11. Brastianos PK, Twohy E, Geyer S, et al. BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med 2023;389(2):118–126. doi:10.1056/NEJMoa2213329. PMID 37437144. verified

Verification (2026-11-17):

Caveats: